Jump to:Page Content
A customer who purchased Enfamil Lipil because it was touted as a unique formulation that was better for babies filed a class action against the formula’s manufacturer, Mead Johnson. The class alleged false advertising and deceptive practices under various state laws. The defendant agreed to a settlement of between $8 million and $12 million, depending on how many claims are made. In re: Enfamil Lipil Mktg. & Sales Pracs. Litig.